Zenas BioPharma, Inc. Common Stock Cash Flow-to-Debt Ratio
Zenas BioPharma, Inc. Common Stock cash flow-to-debt ratio. Zenas BioPharma, Inc. Common Stock (ZBIO) has a Cash Flow-to-Debt Ratio of -0.13x as of June 2026, meaning its operating cash flow of $-57.24 Million could theoretically repay 0% of its total liabilities ($454.59 Million) in one year. Check ZBIO operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Zenas BioPharma, Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for Zenas BioPharma, Inc. Common Stock across 4 annual periods. Check how aggressively does Zenas BioPharma, Inc. Common Stock reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Zenas BioPharma, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
Zenas BioPharma, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Zenas BioPharma, Inc. Common Stock. For the full cash flow conversion analysis, see ZBIO cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.22x | $-172.33 Million | $141.50 Million | ▲ +41.5% |
| 2024 | -2.08x | $-119.67 Million | $57.51 Million | ▼ -1903.3% |
| 2023 | -0.10x | $-30.53 Million | $293.90 Million | ▲ +57.8% |
| 2022 | -0.25x | $-65.65 Million | $266.87 Million | — |